Fennec Pharmaceuticals closes additional $20M following FDA approval
RTP-based Fennec Pharmaceuticals has closed an additional $20 million in funding following the initial close of $5 million in August.
Read More
Fennec Pharmaceuticals
Fennec Pharma raises $30M through stock offering
Fennec Pharmaceuticals has raised some $30 million through a stock offering and says it plans to use the funds to help secure regulatory approval and launch for its lead drug candidate.
Read More
Durham’s Fennec reports Q3 loss, despite progress with trademark drug
Durham-based Fennec Pharmaceuticals reported a net loss of $2.7 million for the third quarter of 2018, even though the company says it’s making progress in regulatory submissions for its trademark drug, Pedmark. Read more here.
Read More
